Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Abemaciclib does not increase the corrected QT interval in healthy participants.
Journal: Clinical and translational science
Published: January 31, 2023
Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: January 10, 2020
Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate.
Journal: Clinical pharmacology and therapeutics
Published: July 06, 2018
Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects.
Journal: Pharmacotherapy
Published: June 11, 2016
Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [(13) C8 ]-evacetrapib as a tracer.
Journal: Journal of labelled compounds & radiopharmaceuticals
Published: August 14, 2015
Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib.
Journal: European journal of clinical pharmacology
Published: June 22, 2015
A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State.
Journal: Journal of cardiovascular pharmacology and therapeutics
Published: October 30, 2014
The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin.
Journal: Platelets
Published: November 12, 2013
Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects.
Journal: Journal of clinical pharmacology
Published: July 11, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026